Biopharma outsourcing change in model use 2021-2023

According to a survey conducted in 2023, over 40 percent of surveyed biopharma executives stated that the usage of the functional service provider (FSP) outsourcing model has increased compared to two years ago. This statistic describes the change in full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2021-2023.

Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2021-2023

Characteristic	Increased use	Decreased use
Full-service	27%	-15%
Functional service provider (FSP)	41%	-7%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

September 2023

More information

Region

Worldwide

Survey time period

March and April 2023

Number of respondents

150 executives

Special properties

respondents from large companies: n=65, from small/mid: n=85

Method of interview

Panel survey

Supplementary notes

The respondents are working for pharma, biopharma, or biotech companies; they have drug development decision-making responsibility and are director-level or above; they work in a role related to drug development; their companies have at least one compound in development; they are from the US/Canada, Europe, and Asia.

Original question: "Over the past two years, how has your company changed its full-service clinical trial outsourcing behavior?"
"Over the past two years, how has your company changed its functional service provider (FSP) outsourcing behavior?"

Citation formats